London, United Kingdom
IXICO is a leading player in the field of end-to-end management and analysis of neuroimaging clinical trials, harnessing the power of expertise and AI.
Since its establishment in 2004, the company has been committed to advancing medicine and human health by converting data into clinically meaningful insights.
Specializing in the provision of neuroimaging services, IXICO assists biopharmaceutical companies in optimizing the value of their drug development pipelines. Through the integration of world-class therapeutic expertise, breakthrough analytics, and operational excellence, the company has emerged as a preferred partner for imaging biomarker solutions in CNS (Central Nervous System) clinical trials.
Operating within the biotechnology and healthcare sectors, IXICO has received a notable Post-IPO Equity investment on 09 October 2024.
With its relentless focus on innovation and a proven track record, IXICO stands poised to continue driving significant advancements in the critical field of neuroimaging and clinical trial management.
